Acalabrutinib vs. Ibrutinib in Previously Treated CLL
Dec 19, 2023
In the first head-to-head trial of BTKs in chronic lymphocytic leukemia, acalabrutinib demonstrated non-inferior progression-free survival with less cardiotoxicity and fewer discontinuations due to adverse events when compared to ibrutinib, according to findings presented at the ASCO 2021 Virtual Annual Meeting (Abstract 7500). “Chronic lymphocytic leukemia, for a long time, has been treated with chemotherapy,” said study author John C. Byrd, MD, Distinguished University Professor and D. Warren Brown Chair of Leukemia Research at OSUCCC-James. “The introduction of targeted therapies with the BTK inhibitor ibrutinib completely changed the landscape of treatment.” Ibrutinib, an irreversible, first-generation BTK, has demonstrated significant benefit over chemotherapy; however, it has a variety of alternative targets that have been associated with toxicity and treatment cessation, Byrd noted.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…